The administration of rabies ribonucleocapsid (RNP) by oral as well as parenteral routes was found to prime specific T cells and elicit N-protein-specific antibodies. per os and intramuscular immunization led to the production of antibodies of the IgA and IgG isotypes, respectively. Mice primed orally with RNP produced significantly enhanced amounts of virus-neutraliing antibody, compared with nonimmune controls, upon subsequent parenteral booster immunization with inactivated rabies virus. Thus oral immunization with rabies RNP primed cells capable of mediating a secondary systemic response to rabies virus. The results of experiments in which peptide and protein antigens were administered either physically coupled to or mixed with RNP indicate that RNP has an inherent capacity to enhance immune responses.
While oral immunization has generally proven to be problematical, both live-attenuated rabies and vaccinia-rabies glycoprotein recombinant virus delivered in edible bait have proven to be effective vaccines (1) (2) (3) . Since rabies virus infection initiates from skin or muscle by a bite, it is clear that the ingested bait vaccines induce a systemic immune response rather than the mucosal response and systemic tolerance that often accompany the feeding of antigen (4) (5) (6) . It is conceivable that the ability of the live vaccines to replicate is important in generating systemic immunity when administered per os (p.o.). However, there is recent evidence to suggest that ingested killed rabies virus or rabies virus proteins also induce protective immunity (7, 8) .
Although virus-neutralizing antibodies are invariably directed at the rabies glycoprotein, several previous studies have indicated that protective immunity to infection with rabies virus can be engendered by the intramuscular (i.m.) administration of the rabies virus ribonucleocapsid (RNP) (9) . Antigenic determinants borne by the N protein of RNP have been implicated in this immunoprotective effect (10) , which is, at least at its inception, independent of virusneutralizing antibodies. Since the antigenic composition of rabies nucleoprotein is more highly conserved than that ofthe glycoprotein (11), a nonreplicating vaccine based on RNP may have more universal applicability. In this investigation we have therefore assessed the immunogenicity of orally administered rabies RNP.
METHODS
Viruses and Antigens. The fixed rabies strains EvelynRokitnicki-Abelseth (ERA) and challenge virus standard (CVS-11) were propagated on BHK-21 cell monolayers and purified as described (12) . The purified virus was suspended in phosphate-buffered saline (PBS), inactivated with (3-propiolactone (PBL) , and adjusted to a protein concentration of 100 pg/ml. Viral RNP was isolated from rabies virus-infected BHK-21 cells (13) , and rabies N protein was purified from insect cells infected with a recombinant baculovirus expressing rabies N protein as described (14) . Keyhole limpet hemocyanin (KLH; catalog no. H-2133) as well as staphylococcal enterotoxins A (SEA; S-9399) and B (SEA; S-4881) were purchased from Sigma. CLTB-36, a human immunodeficiency virus 1 (HIV-1)-derived synthetic peptide including a T-helper cell epitope from the C-terminal end ofthe core protein p24 and a B-cell epitope from the principal neutralization determinant ofV3(MN), as well as HIV-1 pseudovirus were supplied by Connaught Laboratories. CLTB-36 was chemically synthesized using an Applied Biosystems model 430A peptide synthesizer and was coupled to RNP (RNP-CLTB conjugate) as described (15) .
Determination of Antibody Titers. The neutralizing activity of serum from mice immunized with CVS-11 virus was determined as described (16 Cell Culture and Anig4enSpecific Proliferative Assay. Cells were prepared and cultured as described in detail elsewhere (17) . Briefly, single cell suspensions were prepared from aseptically removed spleens by teasing through stainless steel mesh in PBS. Red cells were lysed by hypotonic shock and T cells were isolated by panning on goat anti-mouse immunoglobulin-coated plates. T cells (250,000) from various groups of mice were cultured with unselected spleen cells (100,000-250,000) from nonimmune mice as a source of antigen-presenting cells (APCs) in 200-t4 volumes in roundbottom microtiter plates (Falcon) in the presence of the antigens indicated in the figure legends. Alternatively, T cells were cultured at 0.8 x 106per ml with 1 x 106 irradiated (1000 rads from a cesium source; 1 rad = 0.01 Gy) spleen cells per ml in 2 ml in 24-well flat-bottom plates (Falcon). The medium employed was the a modification of minimum essential medium (GIBCO) supplemented with 4 mM L-glutamine (GIBCO), 0.05 mM 2-mercaptoethanol (Sigma), 25 mM Hepes, 10 pig of gentamycin/ml, and 0.5-0.6% fresh mouse serum. At the indicated times, microtiter cultures or 100I-li samples from 2-ml cultures were pulsed with 1 ACi of [methyl-3H]thymidine (specific activity, 65 Ci/mmol; 1 Ci = 37 GBq; ICN) for 4 hr. The cultures were then harvested using a multiple sample harvester (Skatron, Sterling, VA) and the water-insoluble radioactivity was counted on an LKB rack 13-counter (LKB-Wallac) using conventional liquid scintillation techniques. p.o., but not i.m., immunized mice were given a second dose of antigen by the same route.
The proliferative T cells raised by administration of RNP p.o. and by other routes respond in vitro to rabies virus, purified RNP, as well as purified N protein (data not shown). This is in agreement with previous studies indicating that rabies virus N protein expresses determinants stimulatory for T cells (10) . However, while oral administration of RNP repeatedly resulted in an elevated splenic T-cell response to rabies virus, RNP, and N protein, oral administration of N protein failed to have any comparable effect (data not shown).
Oral RNP Immunization Elicits Serum IgA Antibody. Serum samples from the mice whose T-cell responses were assessed in Fig. 1A were analyzed in a RIA for anti-rabies N-protein antibody. The results of these tests, shown in Fig.  1B (18, 19) . Serum virus-neutralizing antibody titers, which have been correlated with protection from infection, were then determined at various intervals and these are shown in Fig. 2A. Fig. 2B shows a summary of the results obtained with optimal doses of RNP given by the different routes. Regardless of the route of administration, priming with RNP significantly enhanced the antiviral antibody response.
Capacity of RNP To Function as a Carrier for Peptide Antigens. To further examine the carrier effect of RNP evident in the experiment detailed above, we coupled RNP to a peptide antigen, CLTB-36. To ensure that the HIV-derived peptide CLTB-36 conjugated to RNP retained its antigenicity and determine whether it might be immunogenic when administered p.o., we immunized BALB/c mice p.o., as well as C3H mice p.o. and i.m., and tested splenic T cells from these animals for the capacity to respond to CLTB-36. As can be seen in Fig. 3 , a strong proliferative response to CLTB-36 was obtained with cells from C3H mice immunized i.m. (Fig.  3C ), while little reactivity was shown by cells from nonimmune C3H mice (Fig. 3D) . Primed CLTB-36-specific T cells could be detected in BALB (Fig. 3A ) and, to a lesser extent, C3H mice (Fig. 3B ) immunized p.o. As shown in Fig. 4 , the ability of BALB mice to produce anti-HIV antibodies following i.p. immunization with different doses of the pseudovirus is significantly enhanced by prior feeding of RNP-CLTB conjugate. Mechanism of Enhancement and Potential Adjuvant Effect of RNP. The results of the experiments presented above are consistent with the concept that rabies RNP is a particularly good antigen that maintains its immunogenicity when administered p.o. It is conceivable that the known resistance of the RNP complex in acid conditions is responsible for its capacity to immunize when given p.o. Alternatively, or in addition to its stability, RNP may have some inherent antigen-specific or nonspecific capacity to stimulate immunity. For instance, a previous investigation has concluded that rabies virus nucleocapsid may be a superantigen for human T cells (20) . Since superantigens such as SEA and SEB act on both human and murine cells (21) , it is conceivable that this property could contribute to the immunogenicity of RNP in our experiments. We therefore assessed, in our system, the ability of RNP to stimulate T cells and APCs from the spleens of nonimmune C3H mice by comparison with SEA and SEB (Fig. 5) . It is clear that the rapid stimulatory effects of SEA and SEB, which can be seen in the first 24-48 hr of culture, are not shared by RNP.
To examine other possibilities for the strong immunogenicity of rabies RNP, we used i.m. rather than p.o. administration to minimize any contributions from the acid stability of RNP. To distinguish between antigen specific and nonspecific effects, we next compared the immunogenicity of RNP-peptide conjugate with that of a mix of the two components. Fig. 6 shows that i.m. immunization of mice with CLTB alone elicits only a weak response to a high in vitro concentration ofCLTB-36. Enhanced responses to both high and low concentrations of CLTB-36 were obtained when either RNP-CLTB conjugate (Fig. 6C) or a mix of RNP plus CLTB (Fig. 6D) were used to immunize.
Further experiments have demonstrated that RNP can also enhance humoral immune responses to more complex antigens such as KLH. Fig. 7 shows the results of a comparison of i.m. immunization with KLH alone versus a mix of KLH plus RNP. A single dose of a mix of KLH plus RNP was sufficient to induce strong antibody responses to KLH in four of the five mice tested, which were significantly greater than the serum anti-KLH titers seen following administration of KLH alone (data not shown). A second immunization with the same reagents boosted the anti-KLH response in both KLH alone and KLH plus RNP groups, although a large difference in the mean titers was maintained (Fig. 7A) . In this case, the inclusion of RNP in primary and booster immunizations was responsible for an =100-fold difference in the mean serum anti-KLH titers. Moreover, variation in the titers seen in different mice was minimized in the RNP plus KLH group. As shown in Fig. 7B , analysis of the KLHspecific proliferative response of T cells from the spleens of these twice-immunized mice revealed that RNP also enhanced this parameter of immunity. When delivered p.o., most noninvasive and nonreplicating antigens not only are poorly immunogenic but also are likely to induce an antigen-specific systemic hyporesponsiveness termed oral tolerance (4-6). The mechanism oforal tolerance is not fully understood but appears to be due to a deficit in systemic T-cell help (22, 23) . Thus, despite the fact that oral vaccines are desirable for their ease of administration, few exist. Whatever property confers upon RNP the ability to mediate a systemic response after ingestion is evidently somewhat unusual. While we have observed that rabies RNP as well as rabies virus and N protein have the capacity to stimulate nonimmune mouse T cells in vitro (data not shown), these responses are relatively slow to develop and weak when compared with conventional superantigens (Fig. 5) . These findings argue that rabies RNP may have an intrinsic heightened ability to stimulate the immune response irrespective of any capacity to act as a superantigen.
DISCUSSION
Our experiments indicate that the structure ofRNP may be an important aspect of its ability to stimulate by the oral route. N protein, which evidently contains the T-cell determinants of the RNP complex (10, 14) , is not as effective as RNP when both are administered p.o. (data not shown). It is noteworthy that cholera toxin B subunit, a known enhancer of the mucosal immune response (19, 20) , had little effect on p.o. immunization with RNP. We conclude that rabies RNP is sufficiently stimulatory to promote strong immunity whether given by oral or parenteral routes.
The fact that the simultaneous i.m. administration of RNP with different peptide and protein antigens augments humoral responses to the antigens, as well as in vitro antigen-specific T-cell proliferative responses, indicates that RNP may inherently have the ability to function as an adjuvant, possibly through an effect on the APC-T-cell interaction. We believe that this capacity to enhance responses to associated antigens is relevant to the mode of action of RNP in promoting oral immunity.
